Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

358 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Retreatment with TACE: the ABCR SCORE, an aid to the decision-making process.
Adhoute X, Penaranda G, Naude S, Raoul JL, Perrier H, Bayle O, Monnet O, Beaurain P, Bazin C, Pol B, Folgoc GL, Castellani P, Bronowicki JP, Bourlière M. Adhoute X, et al. Among authors: bourliere m. J Hepatol. 2015 Apr;62(4):855-62. doi: 10.1016/j.jhep.2014.11.014. Epub 2014 Nov 21. J Hepatol. 2015. PMID: 25463541
Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C.
de Lédinghen V, Trimoulet P, Winnock M, Foucher J, Bourlière M, Desmorat H, Canva V, Capron D, Lévy S, Mion F, Mannant PR, Chêne G, Fleury H, Couzigou P, Bernard PH; French Multicenter Study Group. de Lédinghen V, et al. Among authors: bourliere m. J Hepatol. 2002 May;36(5):672-80. doi: 10.1016/s0168-8278(02)00026-0. J Hepatol. 2002. PMID: 11983451 Clinical Trial.
Daily or three times per week interferon alpha-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone.
de Lédinghen V, Trimoulet P, Winnock M, Bernard PH, Bourlière M, Portal I, Rémy AJ, Szostak N, Lévy S, Tran A, Abergel A, Chêne G, Fleury H, Couzigou P; French Multicenter Study Group. de Lédinghen V, et al. Among authors: bourliere m. J Hepatol. 2002 Jun;36(6):819-26. doi: 10.1016/s0168-8278(02)00071-5. J Hepatol. 2002. PMID: 12044534 Clinical Trial.
Assessment of early virological response to antiviral therapy by comparing four assays for HCV RNA quantitation using the international unit standard: implications for clinical management of patients with chronic hepatitis C virus infection.
Halfon P, Pénaranda G, Bourlière M, Khiri H, Masseyeff MF, Ouzan D. Halfon P, et al. Among authors: bourliere m. J Med Virol. 2006 Feb;78(2):208-15. doi: 10.1002/jmv.20529. J Med Virol. 2006. PMID: 16372298 Clinical Trial.
Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study.
Halfon P, Bourliere M, Deydier R, Botta-Fridlund D, Renou C, Tran A, Portal I, Allemand I, Bertrand JJ, Rosenthal-Allieri A, Rotily M, Sattonet C, Benderitter T, Saint Paul MC, Bonnot HP, Penaranda G, Degott C, Masseyeff MF, Ouzan D. Halfon P, et al. Among authors: bourliere m. Am J Gastroenterol. 2006 Mar;101(3):547-55. doi: 10.1111/j.1572-0241.2006.00411.x. Am J Gastroenterol. 2006. PMID: 16542291
Multicentre study of hepatitis B virus genotypes in France: correlation with liver fibrosis and hepatitis B e antigen status.
Halfon P, Bourlière M, Pol S, Benhamou Y, Ouzan D, Rotily M, Khiri H, Renou C, Pénaranda G, Saadoun D, Thibault V, Serpaggi J, Varastet M, Tainturier MH, Poynard T, Cacoub P. Halfon P, et al. Among authors: bourliere m. J Viral Hepat. 2006 May;13(5):329-35. doi: 10.1111/j.1365-2893.2005.00692.x. J Viral Hepat. 2006. PMID: 16637864
358 results